ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Michael Gordon of Fenway still part of PMN?

<< Previous

Bullboard Posts

Next >>

Comment by M101on Feb 10, 2022 9:50pm

140 Views

Post# 34418937

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Michael Gordon of Fenway still part of PMN?

The simplest alternative would have been honesty: tell shareholders that as per the Promis theory about highly selective conformational epitopes arising from, and only from, specific pathologic misfolding, the competition is probably all going to fail. That done, congratulating Biogen would have been no problem, and then capitalizing on the subsequent disaster (like right now) also no problem. Honesty is not complicated.

Instead we got Aducanumab plays goldilocks. It was complicated to start with and now it's a dead end mess, but Gene hasn't learned from it.

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports